October 4, 2006 -- ImClone reported a buyout offer of $36 per share that was scuttled by Carl Icahn; Genentech will collaborate with CGI Pharmaceuticals on cancer and autoimmune drug; Keryx in-licensed a cancer drug from a Japanese company; Baxter reported positive results from its bird flu vaccine; Human Genome will begin Phase III testing of Albuferon for hepatitis C; Curis won a patent for agonists of the Hedgehog signaling pathway; Avant extended its collaboration with Pfizer; Nanogen received $20 million from Drug Royalty Corporation; Third Point will begin its proxy fight to remove the Nabi management; and Trubion, LaMaitre Vascular and Catalyst Pharmaceutical Partners proposed terms for their IPOs. The Centient Biotech 200™ climbed 50 points to 3842.47, a rise of 1.37%. More details...
